The Series A round was led by Syncona and included a £1m investment from the UCL Technology Fund.
"It’s really exciting to be in at the start of something that could potentially change the way things are done. By bringing together academia and commerce, Quell Therapeutics will be at the cutting edge of the research and development of this important field."
The company has been named a finalist in the Canada-UK Power Forward Challenge to build smart energy systems.
"Canada and the United Kingdom are investing in better electricity systems. This work will build cleaner, safer, better-connected grids that will also create well-paying jobs for middle-class Canadians. I want to congratulate the Challenge finalists who are growing the economy and creating a cleaner energy future for us all."
The round was led by Merian Chrysalis Investment Company and Arts Alliance.
"There’s no two ways about it – the banks are failing businesses: they have failed to innovate, failed to integrate and, fundamentally, failed to provide SMEs with sufficient capital to grow,"